by Metabolism drugs are used to treat various metabolic disorders such as diabetes, obesity, and other endocrine disorders. These drugs control blood glucose levels, promote weight loss, and regulate hormone function.
The global Metabolism Drugs Market is estimated to be valued at US$ 8169.16 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing prevalence of metabolic diseases such as diabetes and obesity across the globe is the major factor driving the growth of the metabolism drugs market. As per the International Diabetes Federation, around 537 million adults were living with diabetes in 2021, and this number is expected to rise to 783 million by 2045. Similarly, obesity rates are also increasing at an alarming rate globally. Obese and overweight individuals are more prone to developing type 2 diabetes and other comorbidities. Thus, the growing metabolic health issues among the population propel the demand for metabolism drugs for effective treatment of these conditions over the forecast period.
SWOT Analysis
Strength: Metabolism drugs help regulate metabolism in the body, which can treat conditions associated with improper metabolic function like obesity. They have reliable therapeutic effects.
Weakness: Metabolism drugs often have side effects like nausea, diarrhea, and appetite changes. Long-term safety and efficacy data is still limited for some metabolism drugs.
Opportunity: With growing obesity rates worldwide, demand for metabolism drugs is likely to increase to manage weight and treat diabetes and other metabolic disorders. New formulations and delivery methods can expand the viable patient population.
Threats: Alternative therapies like lifestyle modification and bariatric surgery are becoming more common competition. Generic versions of major drugs also pose pricing competition once patents expire. Regulatory approval timelines can impact market entry for novel drugs.
Key Takeaways
The Global Metabolism Drugs Market Growth is expected to witness high over the forecast period. The global Metabolism Drugs Market is estimated to be valued at US$ 8169.16 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030.
North America currently dominates the market due to the high obesity prevalence and frequent medication usage in the region. Europe and Asia Pacific are also sizable markets and expected to grow at above average rates. The Asia Pacific region is expected to grow the fastest due to rising affluence, obesity, and increasing focus on better management of metabolic disorders in major countries like China and India.
Key players: Key players operating in the metabolism drugs market are Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, ASP Cares, Fagron Compounding Pharmacies, Athenex, Inc., Avella Specialty Pharmacy, Atlas Pharmaceuticals, Empower Pharmacy, Carie Boyd€TMS Prescription Shop, Edge Pharma, Imprimis NJOF, LLC, IntegraDose Compounding services, LLC, Wells Pharma of Houston, LLC, US Compounding Inc., and SCA Pharma. Major players are focusing on specialized formulations and expanding geographically to strengthen their positions.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc.
